CASC3 and lung carcinoma: The previous study demonstrated that combination use of TRAIL and Btz could dramatically activate CASP-8 and cause apoptosis in the lung cancer cell line through enhancing the surface expression of TRAIL receptor (Voortman et al., 2007).